Meta Information
ID:astragalus
Name:Astragalus
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:04:55Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/class/immunosuppressants
Target name:
Immunosuppressants
Severity:
moderate
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Astragalus stimulates the immune system, which could oppose drugs used to suppress it (e.g., after transplant or for autoimmune disease).
Actionable advice:
Astragalus is best avoided when taking immunosuppressants unless a specialist approves.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Astragalus is immunostimulant; theoretically antagonizes immunosuppressive therapy. Mechanistic.
Label source:
Class inference
Action type:
avoid
Target id:
/class/antidiabetic-medications
Target name:
Antidiabetic medications
Severity:
minor
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Astragalus may modestly lower blood glucose, adding to diabetes medications.
Actionable advice:
It is a good idea to check glucose if combining, though the effect is usually small.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Astragalus has mild glucose-lowering activity; low-certainty additive effect.
Label source:
Class inference
Action type:
monitor